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Abstract
Interleukin (IL-) 10 is a pleiotropic cytokine with broad immunosuppressive functions, particularly at mucosal sites such as
the intestine and lung. Here we demonstrate that infection of BALB/c mice with respiratory syncytial virus (RSV) induced IL-
10 production by CD4
+ and CD8
+ T cells in the airways at later time points (e.g. day 8); a proportion of these cells also co-
produced IFN-c. Furthermore, RSV infection of IL-10
2/2 mice resulted in more severe disease with enhanced weight loss,
delayed recovery and greater cell infiltration of the respiratory tract without affecting viral load. In addition, IL-10
2/2 mice
had a pronounced airway neutrophilia and heightened levels of pro-inflammatory cytokines and chemokines in the
bronchoalveolar lavage fluid. Notably, the proportion of lung T cells producing IFN-c was enhanced, suggesting that IL-10
may act in an autocrine manner to dampen effector T cell responses. Similar findings were made in mice treated with anti-
IL-10R antibody and infected with RSV. Therefore, IL-10 inhibits disease and inflammation in mice infected with RSV,
especially during recovery from infection.
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Introduction
During acute lung infection, it is imperative that the host’s
inflammatory response is tightly regulated, enabling pathogen
elimination but limiting the detrimental effects of inflammation on
the gas exchange. An appropriate balance of anti-inflammatory
and pro-inflammatory mediators (e.g. IL-10, TGF-b vs. TNF-a,
IFN-c, IL-6) is essential for a safe and effective antiviral immune
response. Thus, an excessive IFN-c response can lead to increased
immunopathology, while exuberant IL-10 production can result in
delayed pathogen clearance [1].
IL-10 can be produced by most cells of the immune system,
including some regulatory T cells [2]. It has many immunosup-
pressive functions, inhibiting production and release of inflamma-
tory cytokines by macrophages and monocytes and thus
maintaining normal immune quiescence at mucosal sites [3,4].
In addition, IL-10 is known to inhibit IL-12 production and
thereby reduce Th1 development and IFN-c production [5].
While inhibiting inflammatory signals, IL-10 also enhances
phagocytic activity, which increases the removal of mediators
and cell debris at sites of inflammation [6].
Epstein-Barr virus (EBV), cytomegalovirus (CMV) and several
poxviruses encode IL-10 homologues [7,8], probably in order to
modulate host responses and possibly to recruit new target cells to
the site of viral replication. Several parasites also induce IL-10
production, probably to allow persistence of infection [9]. Some
bacteria (e.g. Bordetella pertussis) also promote IL-10 production
[10].
Respiratory syncytial virus (RSV) is a major global cause of lower
respiratory tract disease in children, especially those born
prematurely, with low birth weight or suffering from cardiopulmo-
nary disorders [11,12]. RSV bronchiolitis in infancy is associated
with recurrent wheeze in later life [13], and RSV also causes
significant morbidity and mortality in immunosuppressed adults,
those with heart or lung disease and in the elderly [14,15]. Despite
limited viral diversity, immunity to re-infection is only partial,
allowing repeated infections with identical strains, which suggests
that RSV may circumvent or evade normal immune defenses.
Notably, IL-10 is not only detectable in the mouse model of RSV
but also in nasopharyngeal secretions and serum of infants with
severe bronchiolitis [16–18]. The most recent study has suggested a
correlation between local IL-10 levels during the initial RSV
infection and post-bronchiolitis wheeze, providing further evidence
of the importance of IL-10 during human RSV bronchiolitis [18].
Furthermore, Hoebee et al associated risk of severe RSV
bronchiolitis in infants with an IL-10 polymorphism, suggesting
that IL-10 may be important in regulating RSV disease [19].
Two recent studies demonstrate a role for IL-10 in controlling
immunopathology during influenza infection. While one shows that
IL-10 prevents immunopathology and lethal disease [20], the other
indicates that IL-10 has little impact on sublethal infection but
inhibits beneficial Th17 responses during high-dose challenge [21].
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32371Interestingly IL-10 also seems to play a crucial role in controlling
disease severity in RSV infection [22,23]. In both, acute influenza
and RSV infection, CD4
+ and CD8
+ T cells were the major source
of IL-10 and these cells were also able to coproduce IFN-c
[20,21,23]. Another recent study suggested CD4
+ FoxP3
2 and
FoxP3
+ cells to be the IL-10 producers during RSV infection [22].
To further investigate the role of IL-10 in pulmonary immune
responses to RSV infection and provide further evidence to clarify
thecellularsourceofIL-10,we examined the effectsof experimental
RSV infection in IL-10
2/2 mice or mice treated with anti-IL-10
receptor (IL-10R) antibody. We found that IL-10 deficiency during
RSV challenge did not affect viral load, but led to markedly
increased disease severity with enhanced weight loss, delayed
recovery and a greater influx of inflammatory cells intothe lung and
airways and enhanced release of inflammatory mediators. Interest-
ingly, we identified effector CD4
+ and CD8
+ T cells as the main
cellular source of IL-10, and showed that most of those cells co-
produced IFN-c. Our results therefore confirm IL-10 to be a key
anti-inflammatory cytokine responsible for immune regulation in
the lung during acute RSV infection of mice, with Foxp3 negative
CD4
+ and CD8
+ T cells being the main contributors. These data
emphasizethe role that defective immunoregulation mayplay inthe
pathogenesis of severe viral lung disease.
Results
IFN-c and IL-10 co-production by CD4
+ and CD8
+ T cells
during RSV infection
To demonstrate the presence and origin of IL-10 during RSV
infection, BALB/c mice were infected with human RSV A2. Cells
from the lungs and airways were analyzed on day 4 and 8 post
RSV infection for IFN-c and IL-10 expression using flow
cytometry. T cells expressed negligible amounts of IL-10 or
IFN-c in the lung and bronchoalveolar lavage fluid (BAL) on day 4
post RSV infection (not depicted), but both CD4
+ and CD8
+ T
cells from the lung or airways frequently expressed IFN-c and IL-
10 on day 8 post infection (Fig. 1A and B). Interestingly, only
CD8
+ T cells that expressed high levels of IFN-c co-expressed IL-
10 resulting in 6% of CD8 IFN-c producing cells in lung and BAL
co-producing IL-10 and less than 1% IL-10 single producers. In
contrast, up to 8% of CD4 cells in the BAL were IL-10 single-
producers, in addition to 10% of CD4
+ T cells that were IL-10/
IFN-c double-producers (Fig. 1 A and B). Despite the recent
demonstration that Foxp3
+ Tregs are the main producers of IL-10
in RSV disease [22], the majority of our IL-10 expressing CD4
+ T
cells were Foxp3
2 (Fig. 1 C), confirming data highlighting CD4
and CD8 effector cells rather than Foxp3
+ cells as a crucial source
for immunoregulatory IL-10 [23].
Lack of IL-10 increases cellular influx into the lungs and
delays recovery during RSV infection
Since RSV infection induced IL-10 expression by T cells, we
wished to test the effects of IL-10 deficiency on the course of
disease. Therefore, BALB/c WT or IL-10
2/2 mice were infected
with RSV; mice were monitored for disease and daily weight
loss and lung/BAL cells analyzed on day 4 and 8 post infection.
BALB/c IL-10
2/2 mice infected with RSV showed increased
and sustained weight loss and delayed recovery compared to
control BALB/c mice (Fig. 2 A). The absence of IL-10 did not
Figure 1. RSV infection induces IL-10/IFN-c double-producing CD4
+ and CD8
+ T cells in the lung and airways. BALB/c mice were infected with
10
6 PFU RSV i.n. (day 0). CD3
+ gated, CD4
+ T cells and CD8
+ T cells from lungs and airways on day 8 post RSV infection were analyzed by flow cytometry. (A)
Representative plots of intracellular IFN-c and IL-10 expression by CD4
+ and CD8
+ T cells from lung and BAL after a 3 hr PMA/ionomycin restimulation are
shown. (B) Quantifications of the frequencies of single producing IFN-cor IL-10 T cells, and IL-10/IFN-cdouble producing CD4
+and CD8
+Tc e l l so nd a y8p o s t
RSV infection are shown. (C) CD3
+CD4
+ gated T cells and from lungs on day 8 post RSV infection were analyzed for expression of IL-10 and Foxp3 by flow
cytometry. A representative plot and quantifications are shown. The data is representative of three independent experiments each with 4–5 mice per group.
doi:10.1371/journal.pone.0032371.g001
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the time of peak of viral load [24]. However, IL-10-deficient
mice had increased total cell numbers in the lung and BAL on
day 8 post RSV infection (Fig. 2 C) while total cell numbers
in the BAL on day 4 post infection were decreased in IL-10
2/2
mice compared to controls (Fig. 2 C). Notably, the absence
of IL-10 led to an increased efflux of neutrophils in the BAL on
day 8 post RSV infection, but made no difference on day 4
(Fig. 2 D). No eosinophils were detected at any time point in
any of the groups (data not depicted). Unexpectedly, both NK
cells and CD4
+Foxp3
2 T cells were scarcer in the lung on day
4 post RSV infection in the IL-10
2/2 mice (Fig. 2 E).
Furthermore, while the number of CD4
+Foxp3
2 T cells was
similar between the groups on day 8 post infection (data not
depicted), CD8
+ effector T cells were elevated in the lungs of IL-
10
2/2 mice (Fig. 2 E).
Thus, the lack of IL-10 during RSV infection manifests itself as
a markedly increased recruitment of inflammatory CD8
+ T cells to
the lung, enhanced airway neutrophilia and increased disease
severity in the later stage of RSV disease.
Lack of IL-10 increases IFN-c expression in T cells after
RSV infection
IL-10 production by Th1 cells has been reported to act in an
autocrine fashion to dampen IFN-c responses in other patholog-
ical settings [25]. Hence, it was of interest to investigate whether
IL-10 similarly regulated IFN-c expression during RSV infection.
We therefore harvested lung cells from RSV- infected WT or IL-
10-deficient mice and measured IFN-c expression in T cells
following a 3 h restimulation with PMA and ionomycin. Notably,
the lack of IL-10 significantly increased the frequency of IFN-c
+
CD8
+ and CD4
+ T cells in the lung on day 8 post infection (Fig. 3),
supporting the conclusion that IL-10 is important for dampening
the activation of inflammatory T cells during RSV infection.
Blocking IL-10R signalling increases cellular influx into
the lungs and delays recovery during RSV infection
Using IL-10
2/2 mice, we have shown that mice suffer more
severe disease during RSV infection. IL-10
2/2 mice can develop a
spontaneous colitis by 12 wks of age [26] and though we used
young IL-10
2/2 mice (,10 wks), we wanted to confirm our
Figure 2. Lack of IL-10 increases cellular influx into the lungs and delays recovery during RSV infection. BALB/c mice and IL-10
2/2 mice
were infected with 10
6 PFU RSV i.n. (day 0). (A) Illness was monitored daily by changes in weight for 14 days after RSV infection; percentage of original
weight (day 0) is shown. (B) Copies of the RSV L gene were quantified in the lung on day 4 post infection using qPCR. (C) Total numbers of cells in the
lung and BAL were enumerated on day 4 and 8 from naı ¨ve or RSV infected mice. (D) Total numbers of neutrophils in the BAL were quantified using
differential cell counting of H&E stained cytospins slides on day 4 and 8 post infection. (E) Total numbers of NK cells (CD3
2 NKp46
+) and CD3 gated
CD4
+Foxp3
2 and CD8
+ T cells in the lung were quantified using flow cytometry on day 4 and 8 post RSV infection. Error bars indicate the SEM. The
data is representative of three independent experiments with n=4–5 mice per group.
doi:10.1371/journal.pone.0032371.g002
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IL-10-deficiency. Therefore, short-term IL-10 depletion was
achieved by injecting WT BALB/c mice with anti-IL-10 receptor
(aIL-10R) antibody. Mice were either treated with anti-IL-10R,
rat IgG control antibody or left untreated before infection with
RSV. As an index of disease severity, individual body weights were
recorded daily.
In accordance with the IL-10-deficient mice, anti-IL-10R
treated mice infected with RSV showed increased and sustained
weight loss and delayed recovery compared to IgG-treated or
untreated control BALB/c mice (Fig. 4 A). While IL-10R blockade
did not change viral load in the lungs on day 4 post infection
(Fig. 4 B), it did lead to an increase in the total cell numbers in the
lung and BAL on day 8 (Fig. 4 C), as seen in IL-10
2/2 mice.
Interestingly, mice treated with anti-IL-10R antibody also
displayed a decrease in total cell numbers in the BAL on day 4
post infection compared to control BALB/c mice (Fig. 4 C).
Notably, anti-IL-10R treatment also led to an increase in total
numbers of neutrophils in the BAL on day 8 post RSV infection
(Fig. 4 D), while no differences were detected on day 4 (Fig. 4 D).
As seen previously in the IL-10
2/2 mice, NK cells in mice treated
with anti-IL-10R antibody were reduced in the lung on day 4 post
RSV infection (Fig. 4 E). Furthermore, while CD4
+Foxp3
2 T cells
numbers were similar between the two groups of mice on day 8
post infection (Fig. 4 E), CD8
+ effector T cell populations were
elevated in the lungs of mice treated with anti-IL-10R compared
to control or IgG isotype-treated mice (Fig. 4 E).
Therefore, short-term blockade of IL-10R signalling during RSV
infection leads to markedly increased recruitment of inflammatory
cells tothe lung andgreaterdisease severity comparabletoIL-10
2/2
mice, suggesting no crucial secondary adverse effects due to
congenital IL-10 deficiency in this setting.
Lack of IL-10 increases chemokine and cytokine
production in the airways during RSV infection
Chemokine and cytokine expression plays an important role in
the recruitment and activation of different cell types during RSV
infection [27]. To elucidate the role of IL-10 in this response we
measured the levels of mediators in the BAL fluid from naı ¨ve mice,
WT or IL-10
2/2 mice at day 4 and 8 post RSV infection (Fig. 5).
The levels of CXCL1, CXCL10, CCL1, CCL3, IFN-c, TNF-a
and IL-6 were significantly increased in the lungs of RSV-infected
IL-10-deficient mice compared to control mice on day 8 post
infection (Fig. 5). Interestingly, the level of granzyme B (GzmB)
was decreased in BAL fluid of IL-10
2/2 mice on day 4 post RSV
infection, possibly reflecting the reduction in NK cells (a major
source of GzmB [28]) in the airways at this time point.
Overall, these findings suggest that IL-10 acts to limit the
production of diverse inflammatory cytokines and chemokines
during RSV infection, thereby restricting pathology in RSV
disease.
Discussion
We used two different in vivo approaches to examine the
contribution of IL-10 in controlling virally induced lung
inflammation: IL-10
2/2 mice and short-term treatment of WT
mice with anti-IL-10R antibody. We found that lung or airway
CD4
+ and CD8
+ effector T cells were the main source of IL-10,
and the majority of these cells were able to co-produce IFN-c.
Figure 3. Increased frequency of IFN-c-expressing T cells in IL-10
2/2 mice after RSV infection. BALB/c mice were infected with 10
6 PFU
RSV i.n. (day 0). CD3
+ gated, CD4
+ and CD8
+ T cells from lungs on day 8 post RSV infection were analyzed by flow cytometry. Representative plots of
intracellular IFN-c expression after a 3 hr PMA/ionomycin restimulation are shown. In addition, quantifications of the frequencies of IFN-c expression
in CD4
+ T cells and CD8
+ T cells are shown. The data are representative of three independent experiments with n=4–5 mice per group.
doi:10.1371/journal.pone.0032371.g003
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sustained weight loss after RSV infection, accompanied by an
increase in inflammation and cell recruitment to the lung and
airways. Importantly, the general increase in cell recruitment was
reflected in recruitment of neutrophils and CD8
+ T cells..
Together, these findings highlight a central role for IL-10 in
controlling harmful immunopathology.
We confirmed that both CD4
+ and CD8
+ effector T cells were
able to coproduce IL-10 and IFN-c during RSV infection, in line
with recent studies [20,21,23]. Interestingly, we also demonstrated
CD4
+ T cells (but not CD8
+ T cells) that only expressed IL-10, a
phenotype previously attributed to the regulatory subset termed
Tr1 cells [29]. While the significance of IL-10
+ IFN- c
2 CD4
+ T
cells in RSV infection is uncertain, Cardone et al recently
demonstrated in humans that IL 210 expression can occur
through a negative feedback loop via CD46 engagement, which
subsequently induces ‘‘intrinsic’’ IL-10 expression in cells that
previously expressed IFN-c and reveal a Tr1 phenotype [30]. Sun
et al have also recently demonstrated a Th1 phenotype for all IL-10
expressing CD4
+ T cells during RSV infection, but did not
distinguish CD4
+ IL-10
+ T cells from CD4
+ IL-10
+ IFN-c
+ co-
producers during RSV infection [23]. Thus, the phenotype and
function of CD4
+ IL-10
+ IFN-c
2 T cells in the lungs and airways
during RSV infection remain to be elucidated.
Several studies have indicated that Foxp3
+ Tregs are a potential
source of IL-10 [31–34]. However, in contrast to the findings of
Weiss et a, [22] , we did not find that Foxp3
+ Tregs were a major
source of IL-10 . However, we focussed on IL-10 expression by T
cells and therefore we cannot be certain that IL-10 is not produced
by other cell types (e.g. epithelial cells, dendritic cells, macrophag-
es or B cells), especially at early time points after RSV infection.
Interestingly, the absence of IL-10 also altered the NK cell
response in the lung after RSV infection. We found a decrease in
NK cells numbers and reduced GzmB expression by NK cells in
the lungs and airways on day 4 post RSV infection. Stacey et al
recently demonstrated that IL-10R blockade during acute murine
CMV infection resulted in impaired NK cell responsiveness and
proposed that IL-10 acts to promote NK cell activation and
survival in the lung [35]. However, in our model viral load
remained unchanged, implicating that any defect in NK survival
or activation did not affect their ability to kill virus-infected cells.
From our findings that IL-10 is essential for controlling the
inflammatory response during acute viral lung infection, we
propose that IL-10 released by T cells acts in an autocrine fashion
Figure 4. Blocking IL-10R signalling increases cellular influx into the lungs and delays recovery during RSV infection. BALB/c mice
were infected with 10
6 PFU RSV i.n. (day 0). Where indicated, mice were injected with anti-IL-10R antibody on day -1 (i.p.), 3 (i.p. and i.n) and 6 (i.p.)
post RSV infection. Control groups were injected with rat IgG. (A) Illness was monitored daily by changes in weight for 8 days after RSV infection; the
percentage of original weight is shown. (B) Viral titer was measured in the lung on day 4 post infection by quantifying RSV L gene copies by qPCR. (C)
Total numbers of cells in the lung and BAL were enumerated on day 4 and 8 from naı ¨ve or RSV infected mice. (D) Total numbers of neutrophils in the
BAL were quantified using differential cell counting of H&E stained cytospins slides on day 4 and 8 post infection. (E) Total numbers of NK cells (CD3
2
NKp46
+) and CD3-gated, CD4
+Foxp3
2 and CD8
+ T cells in the lung were quantified using flow cytometry on day 4 and 8 post RSV infection. Error bars
indicate the SEM. The data are representative of two independent experiments with n=4–5 mice per group.
doi:10.1371/journal.pone.0032371.g004
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demonstrate that in the absence of IL-10, T cells have increased
levels of IFN-c production, suggesting that IL-10 is necessary to
‘‘self-regulate’’ the T cell response in the lungs and airways at the
peak of the adaptive immune response. These findings were
confirmed in a recent study by Sun et al using CD4-cre IL-10Ra
fl/fl mice. In this study, the specific disruption of IL-10 signalling
in T cells led to increased weight loss and IFN-c levels in the
airways during RSV infection, suggesting a novel autocrine
function of IL-10 in the onset of acute viral lung infection [23].
Pils et al proposed a similar autocrine feedback loop in
macrophages and neutrophils in the model of LPS endotoxemia
[36]. The molecular mechanism and triggers underlying autocrine
IL-10 production by monocytes and effector T cells remains to be
elucidated.
Conversely, IFN-c has also been shown to suppress inflamma-
tion in RSV challenged previously vaccinated mice [37]. Although
IFN-c can be beneficial in limited amounts in RSV-infected mice
its production and anti-inflammatory effects need to be tightly
regulated by expression of IL-10, possibly through an autocrine
loop. Therefore, T cells in IL-10 deficient mice are not able to self-
regulate their IFN-c production and this could contribute to the
elevated immunopathology detected in IL-10 deficient mice in the
later stages of RSV infection.
Our demonstration that IL-10 plays a pivotal role in controlling
immunopathology driven lung inflammation in vivo and the further
highlighting of Foxp3
2 effector T cells as main lymphocytes
producing it is an important step in elucidating the mechanisms by
which the fine balance between clearing virus and controlling
immune responses is achieved in the respiratory tract, allowing
normal gas exchange to be maintained in the face of viral attack.
From these findings, we speculate that selectively enhancing IL-10
production, release or signalling and special consideration of IL-
10/IFN-c double producing CD4 and CD8 effector cells could
potentially be used as a therapeutic strategy to modulate
inflammation in acute viral lung infections, with little risk of
enhancing viral load. Combinations of antiviral medication
with immune modulation are especially promising as a future
therapeutic approach.
Materials and Methods
Ethics statement
All mouse experiments were ethically approved by the Imperial
College Central Biological Services (CBS) ethics committee
performed in accordance with approved UK Home Office
guidelines (Project Licence No. PPL 70/6785).
Mice, virus stocks and infection
Six to ten week old BALB/c IL-10
2/2 mice and BALB/c WT
mice (Harlan, UK) were maintained in pathogen-free conditions
and all experiments were performed in accordance with approved
UK Home Office guidelines.
Plaque-purified human RSV (type A2 strain from the ATCC)
was grown in HEp-2 cells [38]. Age- and sex-matched mice were
lightly anesthetized and infected intranasally (i.n.) with 10
6 PFU
RSV in 100 ml.
Anti-IL-10R antibody treatment
In indicated groups in vivo treatment with anti-IL-10R antibody
(1B1.3a) was performed. Mice were injected intraperitoneally on
day -1, 3 and 6 with 1 mg antibody and intranasally on day 3 with
0.15 mg Ab, and were infected intranasally with 10
6 PFU RSV in
100 ml on day 0. Control groups were treated with equal amounts
of Rat IgG antibody. Both anti-IL10R antibody and anti-IgG
antibody were kindly provided by Anne O’Garra.
Cell collection and preparation
Bronchoalveolar lavage (BAL) was carried out using 1 ml PBS
containing 12 mM Lidocaine and flushing through the trachea 3
times. In order to obtain single cell suspensions, LNs were mashed
through a cell strainer and lungs were incubated with Collagenase
Figure 5. Lack of IL-10 increases chemokine and cytokine production in the airways during RSV infection. BAL samples from BALB/c
and IL-10
2/2 mice were analyzed for indicated cytokines and chemokines on day 4 and 8 after RSV infection using Luminex. A group of naive BALB/c
controls are included in the day 4 data. Error bars indicate the SEM. The data are pooled from two independent experiments with n=4–5 mice per
group.
doi:10.1371/journal.pone.0032371.g005
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dissociator (Miltenyi Biotech) according to the manufacturer’s
protocol. Total cell counts were determined by flow cytometry
using CountBright absolute counting beads (Invitrogen) and dead
cells were excluded using 7-amino-actinomycin D (7-AAD,
Sigma). For determination of cellular composition in the BAL,
cells were transferred onto a microscope slide (Thermo Scientific,
UK) using a cytospin centrifuge and stained with hematoxylin and
eosin (H&E; Reagena, Gamidor, UK).
Flow cytometry
For flow cytometry analysis the LIVE/DEAD Fixable Red
Dead cell stain kit (Invitrogen) was used to exclude dead cells. Cells
were incubated in FACS staining buffer (PBS containing 1% BSA
and 5 mM EDTA) with FccIII/II receptor antibody (BD) and the
following antibodies (from BD Biosciences unless otherwise stated):
V450 or PE conjugated anti-mNKp46/NCR1, PE-Cy7 or V500
conjugated anti-CD3 (145-2C11), Pacific Blue or APC-H7
conjugated anti-CD4 (RM4-5), Alexa Fluor 700 conjugated anti-
CD8a (53-6.7), CD3 APC-Cy7 (17A2) (eBioscience), CD4 Alexa
700 (RM4-5) (eBioscience), CD8 eFluor 450 (53-6.7) (eBioscience),
CD49b PE-Cy7 (DX5) (eBioscience), CD4 PerCp Cy5.5 (RM4-5)
and CD25 PE (3C7). Intracellular staining for Foxp3 and GzmB
was performed using the Foxp3 staining kit (eBioscience) following
manufacturer’s recommendations with the following antibodies:
APC or FITC conjugated anti-Foxp3 (FJK-16s, eBioscience) and
APC conjugated anti-human GzmB (GB12, Caltag, Invitrogen).
Anti-human GzmB antibody cross-reacts with mouse GzmB [39].
For intracellular IFN-c and IL-10 staining, cells were stimulated
with 100 ng/ml PMA and 1 mg/ml Ionomycin in complete RPMI
(RPMI 1640 medium supplemented with 10% fetal bovine serum,
2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml strepto-
mycin). After 1 h incubation, monensin (Golgi Stop, BD) was
added. Following 2 additional hours of incubation, cell surface
staining was followed by intracellular cytokine staining using the
Fix/Perm Kit (BD) with Percp Cy 5.5 anti-IFN-c, PE IL-17
(TC11-18H10) and APC or FITC conjugated IL-10 (JES5-16E3,
eBioscience) antibodies. Cells were acquired on a LSR II (BD,
United Kingdom) with data analyzed using Flow Jo software
(v7.6.5). Cells were gated for live cells, singlets and lymphocytes
before analysis for indicated markers.
Chemokine and cytokine detection
Chemokines and cytokines were quantified by a 24-plex
Luminex kit performed according to the manufacturer’s instruc-
tions (Biolegend) and data acquired with a Luminex 100 (Applied
Cytometry systems). The concentration of cytokines in each
sample was determined according to the standard curve using the
software Starstation. GzmB levels in the BAL were measured by
ELISA following manufacturer’s recommendations (R&D).
Real time quantitative PCR
Total RNA was extracted from homogenized lung tissue using
the Stat60-RNA extraction reagent (AMS Biotechnology Ltd.,
United Kingdom) and transcribed to cDNA by using random
hexamers and Omniscript reverse transcriptase (Qiagen, United
Kingdom). TaqMan real time quantitative PCR was performed
with primers and probes for RSV L gene and 18S rRNA
housekeeping gene as control (Invitrogen if not otherwise stated)
(RSV L gene forward primer 900 nM, (59-GAACTCAGTG-
TAGGTAGAATGTTTGCA-39), RSV L gene reverse primer
300 nM (59-TTCAGCTATCATTTTCTCTGCCAAT-39), L
gene probe 175 nM (59-TTTGAACCTGTCTGAACATTC-
CCGGTT -39) FAM TAMRA (Eurofins MWG Operon), 18S
forward (59-CGCCGCTAGAGGTGAAATTCT-39), 18S reverse
(59-CATTCTTGGCAAATGCTTTCG-39), 18S probe (59-AC-
CGGCGCAAGACGGACCAGA-39) FAM TAMRA, Erofins
MWG Operon) as previously described [38].
Statistical analysis
Results are presented as mean 6 SEM. Statistical significance
was determined using a two-tailed, unpaired Student’s t test
(*p,0.05, **p,0.01, ***p,0.001). Values of p,0.05 were
considered significant (Prism software; Graph-Pad Software Inc.).
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